We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+7.83%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.92B
AUM Growth
-$347M
Cap. Flow
-$415M
Cap. Flow %
-14.2%
Top 10 Hldgs %
63.83%
Holding
68
New
13
Increased
7
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$75.9M
2
VRDN icon
Viridian Therapeutics
VRDN
+$32M
3
MBX
MBX Biosciences
MBX
+$26.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$23.3M
5
RLAY icon
Relay Therapeutics
RLAY
+$18.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$222M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$170M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$153M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$30.5M
5
ITOS
iTeos Therapeutics
ITOS
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETON icon
51
Eton Pharmaceutcials
ETON
$1.28B
$3.4M 0.12%
+566,075
New +$2.39M
PRQR icon
52
ProQR Therapeutics
PRQR
$248M
$3.34M 0.11%
1,835,991
-206,780
-10% -$388K
PRME icon
53
Prime Medicine
PRME
$558M
$2.71M 0.09%
700,000
– –
HOOK
54
DELISTED
HOOKIPA Pharma
HOOK
$2.46M 0.08%
571,727
-5
-0% -$26
ALGS icon
55
Aligos Therapeutics
ALGS
$26.3M
$2.21M 0.08%
255,573
-6
-0% -$75
NUVB.WS
56
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$2.21M 0.08%
963,333
– –
KYTX icon
57
Kyverna Therapeutics
KYTX
$455M
$2.2M 0.08%
450,000
– –
ETON icon
58
CALL
Eton Pharmaceutcials
ETON
$1.28B
$1.37M 0.05%
+228,000
New +$964K
SRZNW icon
59
Surrozen Inc Warrant
SRZNW
$75.6K
$799K 0.03%
66,665
– –
ARTV
60
Artiva Biotherapeutics
ARTV
$512M
$640K 0.02%
+41,453
New +$480K
DSGN icon
61
Design Therapeutics
DSGN
$741M
$290K 0.01%
+53,834
New +$253K
MGNX icon
62
MacroGenics
MGNX
$245M
$184K 0.01%
+56,018
New +$218K
CMAXW
63
DELISTED
CareMax, Inc. Warrant
CMAXW
$170K 0.01%
100,000
– –
ALLK
64
DELISTED
Allakos
ALLK
$126K ﹤0.01%
+192,346
New +$139K
ACAD icon
65
Acadia Pharmaceuticals
ACAD
$4.45B
– –
-1,346,475
Closed -$21.9M
RCKT icon
66
Rocket Pharmaceuticals
RCKT
$343M
– –
-508,393
Closed -$10.9M
SRPT icon
67
Sarepta Therapeutics
SRPT
$1.63B
– –
-1,407,322
Closed -$222M
MORF
68
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-4,982,945
Closed -$170M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2024 Portfolio in Review

As of Q3 2024, EcoR1 Capital held 68 positions worth $2.92B, down 11% from $3.27B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

EcoR1 Capital withdrew a net $415M in Q3 2024, closing 4 positions and reducing 7 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $222M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in Viridian Therapeutics worth $44.6M.

  • EcoR1 Capital's largest Q3 2024 buy was Viridian Therapeutics: 1,958,847 shares worth $44.6M.
  • EcoR1 Capital added most to Jazz Pharmaceuticals in Q3 2024, an estimated $75.9M increase.
  • EcoR1 Capital's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $153M.
  • EcoR1 Capital fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $222M.
  • EcoR1 Capital's ten largest holdings make up 64% of its $2.92B portfolio in Q3 2024.
  • EcoR1 Capital opened 13 new positions and closed 4 in Q3 2024.
  • EcoR1 Capital's portfolio value fell 11% quarter-over-quarter to $2.92B.

Based on EcoR1 Capital's 13F filing for Q3 2024, filed 14 Nov 2024.